Literature DB >> 20198110

Ebolavirus glycoprotein structure and mechanism of entry.

Jeffrey E Lee1, Erica Ollmann Saphire.   

Abstract

Ebolavirus (EBOV) is a highly virulent pathogen capable of causing a severe hemorrhagic fever with 50-90% lethality. The EBOV glycoprotein (GP) is the only virally expressed protein on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion. Hence, the EBOV GP is a critical component of vaccines as well as a target of neutralizing antibodies and inhibitors of attachment and fusion. The crystal structure of the Zaire ebolavirus GP in its trimeric, prefusion conformation (3 GP(1) plus 3 GP(2)) in complex with a neutralizing antibody fragment, derived from a human survivor of the 1995 Kikwit outbreak, was recently determined. This is the first near-complete structure of any filovirus glycoprotein. The overall molecular architecture of the Zaire ebolavirus GP and its role in viral entry and membrane fusion are discussed in this article.

Entities:  

Year:  2009        PMID: 20198110      PMCID: PMC2829775          DOI: 10.2217/fvl.09.56

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  107 in total

1.  Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.

Authors:  Jens H Kuhn; Sheli R Radoshitzky; Alexander C Guth; Kelly L Warfield; Wenhui Li; Martin J Vincent; Jonathan S Towner; Stuart T Nichol; Sina Bavari; Hyeryun Choe; M Javad Aman; Michael Farzan
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

2.  Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.

Authors:  W Weissenhorn; A Carfí; K H Lee; J J Skehel; D C Wiley
Journal:  Mol Cell       Date:  1998-11       Impact factor: 17.970

3.  Processing of the Ebola virus glycoprotein by the proprotein convertase furin.

Authors:  V E Volchkov; H Feldmann; V A Volchkova; H D Klenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

5.  Fruit bats as reservoirs of Ebola virus.

Authors:  Eric M Leroy; Brice Kumulungui; Xavier Pourrut; Pierre Rouquet; Alexandre Hassanin; Philippe Yaba; André Délicat; Janusz T Paweska; Jean-Paul Gonzalez; Robert Swanepoel
Journal:  Nature       Date:  2005-12-01       Impact factor: 49.962

6.  Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates.

Authors:  Peter B Jahrling; Joan B Geisbert; James R Swearengen; Thomas Larsen; Thomas W Geisbert
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  Structure of the Ebola fusion peptide in a membrane-mimetic environment and the interaction with lipid rafts.

Authors:  Mônica S Freitas; Luciane P Gaspar; Marcos Lorenzoni; Fabio C L Almeida; Luzineide W Tinoco; Marcius S Almeida; Lenize F Maia; Léo Degrève; Ana Paula Valente; Jerson L Silva
Journal:  J Biol Chem       Date:  2007-06-01       Impact factor: 5.157

8.  Role of endocytosis and cathepsin-mediated activation in Nipah virus entry.

Authors:  Sandra Diederich; Lena Thiel; Andrea Maisner
Journal:  Virology       Date:  2008-03-14       Impact factor: 3.616

9.  Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Mark G Lewis; Joan B Geisbert; Allen Grolla; Anders Leung; Jason Paragas; Lennox Matthias; Mark A Smith; Steven M Jones; Lisa E Hensley; Heinz Feldmann; Peter B Jahrling
Journal:  PLoS Pathog       Date:  2008-11-28       Impact factor: 6.823

10.  A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L.

Authors:  Cara Theresia Pager; Willie Warren Craft; Jared Patch; Rebecca Ellis Dutch
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

View more
  117 in total

1.  Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry.

Authors:  Derek Dube; Kathryn L Schornberg; Charles J Shoemaker; Sue E Delos; Tzanko S Stantchev; Kathleen A Clouse; Christopher C Broder; Judith M White
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-03       Impact factor: 11.205

2.  Successful delivery of RRT in Ebola virus disease.

Authors:  Michael J Connor; Colleen Kraft; Aneesh K Mehta; Jay B Varkey; G Marshall Lyon; Ian Crozier; Ute Ströher; Bruce S Ribner; Harold A Franch
Journal:  J Am Soc Nephrol       Date:  2014-11-14       Impact factor: 10.121

3.  Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses.

Authors:  Joseph D Bazzill; Sabrina M Stronsky; Laura C Kalinyak; Lukasz J Ochyl; Jesse T Steffens; Sean A van Tongeren; Christopher L Cooper; James J Moon
Journal:  Nanomedicine       Date:  2018-11-22       Impact factor: 5.307

Review 4.  Strategies in Ebola virus disease (EVD) diagnostics at the point of care.

Authors:  Chad T Coarsey; Nwadiuto Esiobu; Ramswamy Narayanan; Mirjana Pavlovic; Hadi Shafiee; Waseem Asghar
Journal:  Crit Rev Microbiol       Date:  2017-04-25       Impact factor: 7.624

Review 5.  Filovirus entry into cells - new insights.

Authors:  Emily Happy Miller; Kartik Chandran
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

6.  Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain α-helical bundle.

Authors:  Joseph S Harrison; Jayne F Koellhoffer; Kartik Chandran; Jonathan R Lai
Journal:  Biochemistry       Date:  2012-03-12       Impact factor: 3.162

7.  Conformational properties of peptides corresponding to the ebolavirus GP2 membrane-proximal external region in the presence of micelle-forming surfactants and lipids.

Authors:  Lauren K Regula; Richard Harris; Fang Wang; Chelsea D Higgins; Jayne F Koellhoffer; Yue Zhao; Kartik Chandran; Jianmin Gao; Mark E Girvin; Jonathan R Lai
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

8.  Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography.

Authors:  Erin E H Tran; James A Simmons; Alberto Bartesaghi; Charles J Shoemaker; Elizabeth Nelson; Judith M White; Sriram Subramaniam
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

9.  Ebolavirus entry requires a compact hydrophobic fist at the tip of the fusion loop.

Authors:  Sonia M Gregory; Per Larsson; Elizabeth A Nelson; Peter M Kasson; Judith M White; Lukas K Tamm
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

Review 10.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.